SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0*

PREAMBLE The Society of Nuclear Medicine (SNM) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. Its 16,000 members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNM also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine. The SNM will periodically define new Practice Guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients throughout the United States. Existing Practice Guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each Practice Guideline, representing a policy statement by the SNM, has undergone a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Committee on SNM Guidelines, Health Policy and Practice Commission, and SNM Board of Directors. The Practice Guidelines recognize that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published Practice Guidelines by those entities not providing these services is not authorized. These Practice Guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNM cautions against the use of these Practice Guidelines in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, an approach that differs from the Practice Guidelines, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the Practice Guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the Practice Guidelines. The practice of medicine involves not only the science, but also the art, of preventing, diagnosing, alleviating, and treating disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these Practice Guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these Practice Guidelines is to assist practitioners in achieving this objective.

[1]  J. Devogelaer,et al.  18F-Fluoride PET for Monitoring Therapeutic Response in Paget’s Disease of Bone , 2005 .

[2]  ICRP Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. , 2008, Annals of the ICRP.

[3]  W. Brenner,et al.  Assessment of the metabolic activity of bone grafts with 18F-fluoride PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Jeannette M. Perez-Rossello,et al.  Skeletal trauma in child abuse: detection with 18F-NaF PET. , 2010, Radiology.

[5]  E. Mittra,et al.  Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study , 2009, Journal of Nuclear Medicine.

[6]  T. Brunkhorst,et al.  Pretherapeutic assessment of tumour metabolism using a dual tracer PET technique , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Anders,et al.  F-18 Fluoride Positron Emission Tomography of the Hip for Osteonecrosis , 2008, Clinical orthopaedics and related research.

[8]  H. Schirrmeister Detection of Bone Metastases in Breast Cancer by Positron Emission Tomography. , 2006, PET clinics.

[9]  S. Wientroub,et al.  Back Pain in Adolescents: Assessment With Integrated 18F-Fluoride Positron-emission Tomography-Computed Tomography , 2007, Journal of pediatric orthopedics.

[10]  M. Zanetti,et al.  Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain , 2010, Skeletal Radiology.

[11]  Eyal Mishani,et al.  Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  S. Ben-Haim,et al.  Breast cancer: role of SPECT and PET in imaging bone metastases. , 2009, Seminars in nuclear medicine.

[13]  H. Schirrmeister,et al.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  D. B. Tuinzing,et al.  No signs of metabolic hyperactivity in patients with unilateral condylar hyperactivity: an in vivo positron emission tomography study. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[16]  I. Fogelman,et al.  The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.

[17]  S. Basu,et al.  Combined 18F-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future? , 2010, Journal of Nuclear Medicine.

[18]  S Ted Treves,et al.  Early Experience With Fluorine-18 Sodium Fluoride Bone PET in Young Patients With Back Pain , 2007, Journal of pediatric orthopedics.

[19]  Christian Schumann,et al.  Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  A. D. Van den Abbeele,et al.  Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw , 2008, Clinical Cancer Research.

[21]  T. Schulz,et al.  Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. , 2009, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[22]  T. Schilling,et al.  Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Lubberink,et al.  Bone Metabolism after Total Hip Revision Surgery with Impacted Grafting: Evaluation using H215O and [18F]fluoride PET; A Pilot Study , 2008, Molecular Imaging and Biology.

[24]  L. Drubach,et al.  Fluorine-18 NaF PET imaging of child abuse , 2008, Pediatric Radiology.

[25]  H. Schirrmeister,et al.  Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. , 2001, Thyroid : official journal of the American Thyroid Association.

[26]  Winfried Brenner,et al.  PET imaging of osteosarcoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  H. Schirrmeister,et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S Ted Treves,et al.  Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer* , 2007, Journal of Nuclear Medicine.

[29]  Eyal Mishani,et al.  18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. , 2007, Seminars in nuclear medicine.

[30]  J. Carrasquillo,et al.  Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  E. Nitzsche,et al.  Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? , 1998, Radiology.

[32]  J. Valentin,et al.  Radiation dose to patients from radiopharmaceuticals: (Addendum 2 to ICRP Publication 53) ICRP Publication 80 Approved by the Commission in September 1997 , 1998, Annals of the ICRP.

[33]  P. Waldenberger,et al.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  R. Takeuchi,et al.  Evaluation of lesion in a spontaneous osteonecrosis of the knee using 18F-fluoride positron emission tomography , 2008, Knee Surgery, Sports Traumatology, Arthroscopy.

[35]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  R. Sparks,et al.  Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. , 1997, Health physics.

[37]  Hisatoshi Baba,et al.  Effects of Alendronate on Bone Metabolism in Glucocorticoid-Induced Osteoporosis Measured by 18F-Fluoride PET: A Prospective Study , 2009, Journal of Nuclear Medicine.

[38]  J. Sörensen,et al.  Bone healing of severe acetabular defects after revision arthroplasty , 2009, Acta orthopaedica.

[39]  W. Wong,et al.  [18F]-fluoride positron emission tomography for imaging condylar hyperplasia. , 2009, The British journal of oral & maxillofacial surgery.

[40]  Mohsen Beheshti,et al.  Prostate cancer: role of SPECT and PET in imaging bone metastases. , 2009, Seminars in nuclear medicine.

[41]  G. Cook,et al.  Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. , 2009, Seminars in nuclear medicine.